Femasys Inc Ordinary Shares FEMY 深 沪
已收盘 12-19 16:00:00 美东时间
0.8505
+0.053
+6.65%
华盛通- 最 高1.04
- 今 开0.85
- 成交量 152.67万股
- 最 低 0.76
- 昨 收 0.7975
- 总市值 1004.75万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 12.92%
- 52周最低 0.3067
- 委 比 -66.67%
- 总股本 1181.36万
- 历史最高 13.75
- 量 比 1.07
- 振 幅 35.11%
- 历史最低 0.2479
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多生物技术公司Femasys重挫35.7%，此前宣布将公开发行募集800万美元资金
美股周二早盘，生物技术公司Femasys（FEMY）股价重挫35.7%，此前该公司宣布通过公开发行募集800万美元资金，所筹资金将用于支持该公司的商业扩张和产品开发计划。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
08-26 23:09
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
Femasys公司任命Kelley Nicholas为首席商业官，负责推动其在美国的不孕症市场扩展及全球合作伙伴关系。Nicholas拥有超过25年的医疗行业经验，在商业执行和市场扩展方面成绩显著。她将领导Femasys的商业战略，以FemaSeed®等产品为中心，提升公司在女性健康领域的地位。Femasys专注于开发创新的生育和诊断产品，填补未满足的市场需求。
06-17 13:00
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
Femasys partners with Carolinas Fertility Institute to expand access to its FemaSeed® intratubal insemination product, offering a less invasive, cost-effective infertility treatment option. The collaboration supports women earlier in their fertility journey with a solution that outperforms traditional IUI. FemaSeed is now available at CFI's network in North Carolina.
06-11 13:00
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
Femasys Inc. announced an underwritten public offering of 3.6 million shares at $0.85 per share and a concurrent private placement of 1.686 million shares, totaling approximately $4.5 million. Proceeds will be used for product development, commercial expansion, and general corporate purposes. The offering and placement are expected to close on June 2, 2025, with an option for the underwriter to purchase up to an additional 540,000 shares.
05-30 12:00
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Femasys Inc. plans to offer shares of its common stock in an underwritten public offering, with an option for underwriters to purchase up to an additional 15% of shares. The company also expects a concurrent private placement by certain institutional stockholders, directors, and officers. The offerings are subject to market conditions, and proceeds will be used for commercial expansion, product development, and general corporate purposes.
05-29 20:23
North Dakota Judge Overturns State's Abortion Ban, Making Abortion Legal In The State
- Reuters
2024-09-13 01:53
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Femasys (NASDAQ:FEMY) has been analyzed by 4 analysts in the last three months,...
2024-09-12 20:01
HC Wainwright & Co. Reiterates Buy on Femasys, Maintains $12 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $12 price target.
2024-09-12 18:19
Femasys Secures Strategic Distribution Partnerships For Commercialization Of FemaSeed For Over $1.3M In Spanish Market
Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic
2024-09-11 20:31
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) rose sharply in today's pre-ma...
2024-09-09 18:08
